2
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Dermatologic
1
Conditions
Hemorrhage
13
Neoplasms
7
Leiomyoma
7
Breast Neoplasms
6
Postoperative Hemorrhage
4
Hematologic Neoplasms
4
Thrombocytopenia
3
Myofibroma
3
Meningioma
3
Blood Loss, Surgical
3
Urinary Bladder Neoplasms
2
Stomach Neoplasms
2
Seroma
2
Seizures
2
Prostatic Neoplasms
2
Postoperative Complications
2
Ovarian Neoplasms
2
Menorrhagia
2
Head and Neck Neoplasms
2
Colonic Neoplasms
2
Brain Neoplasms
2
Bone Neoplasms
2
Wrist Fractures
1
Urologic Diseases
1
Urinary Tract Infections
1
Urinary Retention
1
Thromboembolism
1
Staphylococcal Infections
1
Spasm
1
Sleep Initiation and Maintenance Disorders
1
Interventions
pembrolizumab
300
Nivolumab
273
Ipilimumab
250
aldesleukin
137
Cyclophosphamide
135
Interleukin-2
105
trametinib
82
dabrafenib
76
Temozolomide
75
Dacarbazine
74
Vemurafenib
71
fludarabine
67
fludarabine phosphate
61
Biopsy
49
binimetinib
47
sargramostim
44
Radiosurgery
44
Bevacizumab
43
Paclitaxel
42
encorafenib
40
incomplete Freund's adjuvant
39
atezolizumab
38
Radiotherapy
37
Cisplatin
36
CTLA-4 Antigen
36
Carboplatin
35
cobimetinib
34
Specimen Handling
34
Magnetic Resonance Spectroscopy
34
Introns
33
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Melanoma
×
Tranexamic Acid
×
Clear all
NCT05899465
2025-03-18
PRIME
University of Aarhus
Phase 3
Recruiting
1,204 enrolled